Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joshua Cohen
The drug industry and patient advocacy groups have been leery about the imposition of price controls or restrictions on reimbursement for drugs that treat orphan diseases. A review of formulary data from the beginning of the century shows that there has been some pushback from payers about these high-priced drugs, but patient access has not been severely hampered to date.
Singling out prescription drugs as the most egregious of the health care cost sinners in spite of their relatively small role raises the question of why the media and peer-reviewed journals pay so much attention to their cost. Analysts and policymakers should avoid a myopic silo mentality and instead adopt a holistic approach that measures the value and budgetary impact of health care services across all sectors.
Zarxio is the first in an expected wave of US biosimilar approvals as blockbuster originator biologics go off patent. Just as market competition for small molecules has proven to be healthy for both generics and brand-name biopharmas, competition for biologics will likely have similar effects.